Wu Q, Fu J, Zhu B, Meng W, Ma J, Lv Y
Cell Commun Signal. 2025; 23(1):52.
PMID: 39875989
PMC: 11773936.
DOI: 10.1186/s12964-025-02045-x.
Briones A, Del Estal L, Villa-Gomez C, Bermejo V, Cervera I, Gutierrez-Huerta P
Int J Mol Sci. 2025; 26(2).
PMID: 39859310
PMC: 11765243.
DOI: 10.3390/ijms26020595.
Chan K, Faiz S, Altan M, Sheshadri A
J Immunother Precis Oncol. 2024; 7(4):272-282.
PMID: 39524467
PMC: 11541925.
DOI: 10.36401/JIPO-24-12.
Zierden M, Berghausen E, Gnatzy-Feik L, Millarg C, Picard F, Kiljan M
JCI Insight. 2024; 9(22).
PMID: 39378110
PMC: 11601942.
DOI: 10.1172/jci.insight.155626.
Alviano A, Biondi M, Grassenis E, Biondi A, Serafini M, Tettamanti S
Front Immunol. 2024; 15:1407992.
PMID: 38887285
PMC: 11180895.
DOI: 10.3389/fimmu.2024.1407992.
Activated PI3Kδ Specifically Perturbs Mouse Regulatory T Cell Homeostasis and Function Leading to Immune Dysregulation.
Singh A, Al Qureshah F, Drow T, Hou B, Rawlings D
J Immunol. 2024; 213(2):135-147.
PMID: 38829130
PMC: 11232928.
DOI: 10.4049/jimmunol.2400032.
Activated PI3Kδ specifically perturbs mouse Treg homeostasis and function leading to immune dysregulation.
Singh A, Al Qureshah F, Drow T, Hou B, Rawlings D
bioRxiv. 2024; .
PMID: 38187650
PMC: 10769388.
DOI: 10.1101/2023.12.21.569665.
SUMOylation patterns and signature characterize the tumor microenvironment and predict prognosis in lung adenocarcinoma.
Chen Z, Yang J, Tang L, Sun X, Li Y, Sheng Z
Front Cell Dev Biol. 2023; 11:1094588.
PMID: 37123398
PMC: 10133499.
DOI: 10.3389/fcell.2023.1094588.
Severe COVID-19: Drugs and Clinical Trials.
Ceja-Galvez H, Renteria-Flores F, Nicoletti F, Hernandez-Bello J, Macedo-Ojeda G, Munoz-Valle J
J Clin Med. 2023; 12(8).
PMID: 37109231
PMC: 10142549.
DOI: 10.3390/jcm12082893.
PHLPP Signaling in Immune Cells.
Lorden G, Lam A, Levings M, Newton A
Curr Top Microbiol Immunol. 2022; 436:117-143.
PMID: 36243842
DOI: 10.1007/978-3-031-06566-8_5.
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?.
Skanland S, Brown J
Haematologica. 2022; 108(1):9-21.
PMID: 35899388
PMC: 9827175.
DOI: 10.3324/haematol.2022.281266.
Regulation of Treg Cell Metabolism and Function in Non-Lymphoid Tissues.
Yang K
Front Immunol. 2022; 13:909705.
PMID: 35720275
PMC: 9200993.
DOI: 10.3389/fimmu.2022.909705.
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.
Lew T, Anderson M, Seymour J
Cancer Drug Resist. 2022; 3(3):415-444.
PMID: 35582452
PMC: 8992498.
DOI: 10.20517/cdr.2019.108.
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.
Navarro-Ocon A, Blaya-Canovas J, Lopez-Tejada A, Blancas I, Sanchez-Martin R, Garrido M
Pharmaceutics. 2022; 14(3).
PMID: 35335881
PMC: 8950730.
DOI: 10.3390/pharmaceutics14030505.
PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.
Hus I, Pula B, Robak T
Cancers (Basel). 2022; 14(6).
PMID: 35326722
PMC: 8945984.
DOI: 10.3390/cancers14061571.
Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors.
Gadkar K, Friedrich C, Hurez V, Ruiz M, Dickmann L, Jolly M
CPT Pharmacometrics Syst Pharmacol. 2021; 11(5):616-627.
PMID: 34850607
PMC: 9124351.
DOI: 10.1002/psp4.12749.
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients.
Tarantelli C, Argnani L, Zinzani P, Bertoni F
Cancers (Basel). 2021; 13(21).
PMID: 34771694
PMC: 8582887.
DOI: 10.3390/cancers13215535.
Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients.
Abu-Eid R, Ward F
Immunol Lett. 2021; 240:1-8.
PMID: 34562551
PMC: 8457906.
DOI: 10.1016/j.imlet.2021.09.005.
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Chandrasekaran S, Ronald Funk C, Kleber T, Paulos C, Shanmugam M, Waller E
Front Immunol. 2021; 12:718621.
PMID: 34512641
PMC: 8427697.
DOI: 10.3389/fimmu.2021.718621.
PI3-Kinase p110α Deficiency Modulates T Cell Homeostasis and Function and Attenuates Experimental Allergic Encephalitis in Mature Mice.
Rojo J, Montes-Casado M, Aragoneses-Fenoll L, Ojeda G, Dianzani U, Portoles P
Int J Mol Sci. 2021; 22(16).
PMID: 34445401
PMC: 8395417.
DOI: 10.3390/ijms22168698.